{"disease":{"id":"pyoderma-gangrenosum","name":"Pyoderma gangrenosum","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":5,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"abrilada","indication_name":"Pyoderma gangrenosum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"adalimumab","indication_name":"Pyoderma gangrenosum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"adalimumab-adbm","indication_name":"Pyoderma gangrenosum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"clofazimine","indication_name":"Pyoderma gangrenosum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamprene","generic_name":"clofazimine","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Antimycobacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"humira","indication_name":"Pyoderma gangrenosum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04792957","title":"JAK-STAT Signaling Pathway in Pyoderma Gangrenosum","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Dokuz Eylul University","has_results":false},{"nct_id":"NCT06624670","title":"A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT04750213","title":"A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT05964413","title":"Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":54,"lead_sponsor_name":"InflaRx GmbH","has_results":false},{"nct_id":"NCT03311464","title":"A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03971643","title":"Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"InflaRx GmbH","has_results":true},{"nct_id":"NCT06563323","title":"Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":17,"lead_sponsor_name":"Oregon Health and Science University","has_results":false},{"nct_id":"NCT01965613","title":"A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04895566","title":"Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"SWISS BIOPHARMA MED GmbH","has_results":false},{"nct_id":"NCT06092216","title":"Spesolimab in Pyoderma Gangrenosum","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":true},{"nct_id":"NCT05120726","title":"A Novel Therapeutic Treatment of Pyoderma Gangrenosum","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Louisiana State University Health Sciences Center in New Orleans","has_results":false},{"nct_id":"NCT04901325","title":"Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Oregon Health and Science University","has_results":false},{"nct_id":"NCT03137160","title":"An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Ohio State University","has_results":true},{"nct_id":"NCT05343754","title":"Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT03072953","title":"Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Arena Pharmaceuticals","has_results":true},{"nct_id":"NCT05984654","title":"Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Ohio State University","has_results":false},{"nct_id":"NCT05821374","title":"Deucravacitinib in PG","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":false}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}